India’s patent office decided to reject pharma giant Johnson &Johnson’s appeal to extend the patent for a life-saving TB medicine called bedaquiline which is used to treat those with drug resistant infections.
But for a long time before this, Johnson & Johnson was enjoying a monopoly in India. Generic manufacturers could not make this life-saving medicine. The Indian government too, at the time, had decided to protect the pharma giant.
Not just that, Johnson & Johnson was also conveniently projecting itself as a charitable organisation through its health programmes.
What does the Indian govt’s decision mean for TB patients in India now?
If you are a student who wants to participate in The Ken's case build competition, or if you simply want to read the case, you can do that here:
What is Daybreak?
Business news is complex and overwhelming. It doesn’t have to be. Every day of the week, from Monday to Friday, Daybreak tells one business story that’s significant, simple and powerful.
Hosted from The Ken’s newsroom by Snigdha Sharma and Rahel Philipose, Daybreak relies on years of original reporting and analysis by some of India’s most experienced and talented business journalists.